Advanced Oncotherapy Stock | AVO.L | GB00BD6SX109 | A2AL9X

Date	Advanced Oncotherapy Price
5/8/2024	0.00 undefined
5/7/2024	0.00 undefined

Date	Advanced Oncotherapy Revenue	Advanced Oncotherapy EBIT	Advanced Oncotherapy Net Income
2027e	211.91 M undefined	39.69 M undefined	23.08 M undefined
2026e	176.57 M undefined	19.24 M undefined	10.45 M undefined
2025e	149.24 M undefined	5.85 M undefined	2.24 M undefined
2024e	103.31 M undefined	-9.58 M undefined	-8.94 M undefined
2023e	34.4 M undefined	-26.37 M undefined	-25.15 M undefined
2022e	0 undefined	-27.81 M undefined	-38.56 M undefined
2021	0 undefined	-23.74 M undefined	-29.49 M undefined
2020	0 undefined	-20.27 M undefined	-25.3 M undefined
2019	0 undefined	-20.66 M undefined	-20.79 M undefined
2018	0 undefined	-21.85 M undefined	-21.15 M undefined
2017	0 undefined	-14.49 M undefined	-13.66 M undefined
2016	0 undefined	-13.09 M undefined	-10.35 M undefined
2015	0 undefined	-7.62 M undefined	-6.56 M undefined
2014	0 undefined	-4.16 M undefined	-7.46 M undefined
2013	70,000 undefined	-2.12 M undefined	-3.94 M undefined
2012	100,000 undefined	-1.06 M undefined	-2.71 M undefined
2011	6.16 M undefined	-670,000 undefined	-6.49 M undefined
2010	3.4 M undefined	-1.14 M undefined	-4.09 M undefined
2009	3.41 M undefined	1.74 M undefined	-1.9 M undefined
2008	2.86 M undefined	-970,000 undefined	-1.69 M undefined
2007	2.12 M undefined	2.74 M undefined	1.35 M undefined
2006	1.83 M undefined	3.18 M undefined	680,000 undefined
2005	1.75 M undefined	310,000 undefined	-600,000 undefined
2004	560,000 undefined	110,000 undefined	-180,000 undefined

	Revenue	EBIT	Net Income
2004	560,000 GBP	110,000 GBP	-180,000 GBP
2005	1.75 M GBP	310,000 GBP	-600,000 GBP
2006	1.83 M GBP	3.18 M GBP	680,000 GBP
2007	2.12 M GBP	2.74 M GBP	1.35 M GBP
2008	2.86 M GBP	-970,000 GBP	-1.69 M GBP
2009	3.41 M GBP	1.74 M GBP	-1.9 M GBP
2010	3.4 M GBP	-1.14 M GBP	-4.09 M GBP
2011	6.16 M GBP	-670,000 GBP	-6.49 M GBP
2012	100,000 GBP	-1.06 M GBP	-2.71 M GBP
2013	70,000 GBP	-2.12 M GBP	-3.94 M GBP
2014	0 GBP	-4.16 M GBP	-7.46 M GBP
2015	0 GBP	-7.62 M GBP	-6.56 M GBP
2016	0 GBP	-13.09 M GBP	-10.35 M GBP
2017	0 GBP	-14.49 M GBP	-13.66 M GBP
2018	0 GBP	-21.85 M GBP	-21.15 M GBP
2019	0 GBP	-20.66 M GBP	-20.79 M GBP
2020	0 GBP	-20.27 M GBP	-25.3 M GBP
2021	0 GBP	-23.74 M GBP	-29.49 M GBP
2022e	0 GBP	-27.81 M GBP	-38.56 M GBP
2023e	34.4 M GBP	-26.37 M GBP	-25.15 M GBP
2024e	103.31 M GBP	-9.58 M GBP	-8.94 M GBP
2025e	149.24 M GBP	5.85 M GBP	2.24 M GBP
2026e	176.57 M GBP	19.24 M GBP	10.45 M GBP
2027e	211.91 M GBP	39.69 M GBP	23.08 M GBP

2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021

7.94	6.97	2.53	0.12	2.52	0.08	0.15	0.02	0.06	0.15	1.47	8.96	1.45	0.06	1.01	3.24	2.32	4.26
190	340	360	150	130	170	280	10	0	30	73.57	0	0	0	0	0	0	0
0.01	0.01	0.17	0.14	0.16	0.21	2.19	1.4	1.42	1.08	0.39	2.9	3.3	4.28	0	0	0	0
0	0	0	0	0	0	0	0	0	0.04	1.11	4.42	7.44	7.63	10.01	15.05	22.14	25.83
0.06	0.03	0.04	0.25	0.18	0.32	0.08	0.03	0.03	0.09	0.12	0.41	0.35	0.53	1.18	1.69	0.98	0.42
8.2	7.35	3.1	0.66	2.99	0.78	2.7	1.46	1.51	1.39	3.17	16.68	12.54	12.5	12.21	19.97	25.43	30.51
20.61	21.54	0.03	0.15	0.14	0.12	0.1	0.01	0.21	0.67	0.88	1	1.46	1.18	4.09	38.53	38.15	41.06
0	0	30.02	42.82	55.85	60.06	34.08	5.43	3.05	2.01	1.2	0.31	0.31	0.31	0.31	0	0	0
0	0	0	0	0	0	0	0.17	0.87	0	0	0	0	0.84	1.21	0.91	0.93	0.93
0.36	0.28	1.75	0	1.75	0	0	0	0	6.69	9.22	12.74	23.36	30.57	40.17	49.18	56.87	68.58
0	0	0	1.95	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	1.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
20.97	21.82	33.3	44.92	57.74	60.18	34.18	5.61	4.13	9.37	11.3	14.06	25.13	32.9	45.77	88.63	95.95	110.56
29.17	29.17	36.4	45.58	60.73	60.96	36.88	7.07	5.64	10.76	14.47	30.74	37.67	45.4	57.98	108.6	121.38	141.07

11.75	11.75	0.77	0.77	0.77	0.77	0.77	0.77	2.59	6.04	10.28	14.18	18.12	20.23	42.39	61.11	83.36	112.9
0	0.28	1.54	1.61	1.79	1.81	1.96	1.96	2.25	6.87	14.66	32.82	43.12	43.26	50.72	60.45	61.44	71.09
-0.18	-0.78	11.07	12.43	10.74	8.83	4.74	-1.86	-4.59	-7.16	-14.1	-19.64	-28.77	-40.94	-60.57	-79.61	-103.55	-124.74
0	0	0	0	0.44	-0.14	-0.44	-0.39	-0.39	-0.39	0.29	-0.08	1.53	6.11	1.45	0.99	2.89	2.12
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
11.57	11.25	13.38	14.81	13.74	11.27	7.03	0.48	-0.14	5.36	11.13	27.28	33.99	28.66	34	42.94	44.14	61.37
0.04	0.11	0.14	0.21	0.44	0.35	1.28	1.62	0.96	0.72	1.14	0.34	1.58	4.03	2.78	1.85	1.6	2.45
0.44	0.41	0.8	0.57	1.01	1.8	1.33	1.16	1.01	1.47	1.2	1.96	1.4	3.46	3.18	3.03	4.84	2.9
170	160	250	100	490	310	0	10	10	0	0	161.03	161.03	0	0	0	0	0
0	0	0	1.98	3.65	5.25	3.65	1.22	1.22	0.61	0	0	0	0	0	0	0	0
0.37	0.37	0.37	0.41	0.79	3.96	3.73	2.58	2.58	2.58	0.99	1	0.54	9.25	3	1.59	12.77	10.77
1.02	1.05	1.56	3.27	6.38	11.67	9.99	6.59	5.78	5.38	3.33	3.46	3.68	16.74	8.95	6.48	19.21	16.12
13.79	13.98	18.51	24.75	38.33	37.38	19.44	0	0	0	0	0	0	0	0	44.91	37.86	42.58
0	0	2.25	2.63	2.1	0.41	0.29	0	0	0	0	0	0	0	0	0	0	0
2.79	2.89	0.7	0	0	0	0	0	0	0	0	0	0	0	16.5	16.5	21.08	21.22
16.58	16.87	21.46	27.38	40.43	37.79	19.73	0	0	0	0	0	0	0	16.5	61.41	58.94	63.8
17.6	17.92	23.02	30.65	46.81	49.46	29.72	6.59	5.78	5.38	3.33	3.46	3.68	16.74	25.45	67.89	78.15	79.92
29.17	29.17	36.4	45.46	60.55	60.73	36.75	7.07	5.64	10.74	14.47	30.74	37.67	45.4	59.45	110.82	122.29	141.29

2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
0	0	0	1,000	-1,000	-1,000	-4,000	-6,000	-2,000	-3,000	-5,000	-5,000	-10,000	-13,000	-21,000	-20,000	-25,000	-29,000
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	2
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	-1	-1	-1	-4	-1	0	0	0	-3	0	3	12	-6	-4	-11
0	0	-2	-1	2	2	4	7	1	1	0	0	0	0	6	2	6	9
0	1	1	1	2	2	1	1	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	-2	-2	-3	-2	0	-1	0
0	0	-1	-1	0	0	-4	0	-1	-2	-6	-9	-10	-9	-1	-23	-20	-29
0	0	0	-2	-8	-6	0	0	0	0	-1	-4	-9	-8	-12	-12	-7	-9
0	0	-6	-8	-9	-6	23	24	0	0	-1	-3	-9	-8	-12	-11	-7	-9
0	0	-5	-5	0	0	23	24	0	1	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	1	6	13	4	-19	-23	1	0	-2	0	0	16	-5	12	9	-3
7	0	1	0	0	0	0	0	1	2	10	21	13	0	21	25	18	43
8	0	3	5	13	4	-19	-23	2	2	9	21	13	16	14	37	26	40
0	0	0	0	0	0	0	0	0	0	1,000	0	0	0	0	0	-1,000	1,000
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
7	0	-4	-4	4	-2	0	0	0	0	1	7	-7	-1	0	2	0	1
-0.25	-1.23	-2.17	-4.06	-9.12	-7.06	-4.39	-1.1	-2.06	-3.67	-7.81	-14.13	-20.61	-18.15	-13.76	-35.56	-27.68	-38.86
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Advanced Oncotherapy Gross margin	Advanced Oncotherapy Profit margin	Advanced Oncotherapy EBIT margin	Advanced Oncotherapy Profit margin
2027e	-128.57 %	18.73 %	10.89 %
2026e	-128.57 %	10.89 %	5.92 %
2025e	-128.57 %	3.92 %	1.5 %
2024e	-128.57 %	-9.27 %	-8.66 %
2023e	-128.57 %	-76.65 %	-73.1 %
2022e	-128.57 %	0 %	0 %
2021	-128.57 %	0 %	0 %
2020	-128.57 %	0 %	0 %
2019	-128.57 %	0 %	0 %
2018	-128.57 %	0 %	0 %
2017	-128.57 %	0 %	0 %
2016	-128.57 %	0 %	0 %
2015	-128.57 %	0 %	0 %
2014	-128.57 %	0 %	0 %
2013	-128.57 %	-3,028.57 %	-5,628.57 %
2012	100 %	-1,060 %	-2,710 %
2011	15.42 %	-10.88 %	-105.36 %
2010	50 %	-33.53 %	-120.29 %
2009	86.51 %	51.03 %	-55.72 %
2008	85.31 %	-33.92 %	-59.09 %
2007	91.98 %	129.25 %	63.68 %
2006	95.63 %	173.77 %	37.16 %
2005	96 %	17.71 %	-34.29 %
2004	96.43 %	19.64 %	-32.14 %

	Gross margin	EBIT margin	Profit margin
2004	96.43 %	19.64 %	-32.14 %
2005	96 %	17.71 %	-34.29 %
2006	95.63 %	173.77 %	37.16 %
2007	91.98 %	129.25 %	63.68 %
2008	85.31 %	-33.92 %	-59.09 %
2009	86.51 %	51.03 %	-55.72 %
2010	50 %	-33.53 %	-120.29 %
2011	15.42 %	-10.88 %	-105.36 %
2012	100 %	-1,060 %	-2,710 %
2013	-128.57 %	-3,028.57 %	-5,628.57 %
2014	-128.57 %	0 %	0 %
2015	-128.57 %	0 %	0 %
2016	-128.57 %	0 %	0 %
2017	-128.57 %	0 %	0 %
2018	-128.57 %	0 %	0 %
2019	-128.57 %	0 %	0 %
2020	-128.57 %	0 %	0 %
2021	-128.57 %	0 %	0 %
2022e	-128.57 %	0 %	0 %
2023e	-128.57 %	-76.65 %	-73.1 %
2024e	-128.57 %	-9.27 %	-8.66 %
2025e	-128.57 %	3.92 %	1.5 %
2026e	-128.57 %	10.89 %	5.92 %
2027e	-128.57 %	18.73 %	10.89 %

Date	Advanced Oncotherapy Sales per Share	Advanced Oncotherapy EBIT per share	Advanced Oncotherapy Earnings per Share
2027e	0.39 undefined	0 undefined	0.04 undefined
2026e	0.33 undefined	0 undefined	0.02 undefined
2025e	0.28 undefined	0 undefined	0 undefined
2024e	0.19 undefined	0 undefined	-0.02 undefined
2023e	0.06 undefined	0 undefined	-0.05 undefined
2022e	0 undefined	0 undefined	-0.07 undefined
2021	0 undefined	-0.06 undefined	-0.08 undefined
2020	0 undefined	-0.07 undefined	-0.09 undefined
2019	0 undefined	-0.1 undefined	-0.1 undefined
2018	0 undefined	-0.15 undefined	-0.14 undefined
2017	0 undefined	-0.19 undefined	-0.18 undefined
2016	0 undefined	-0.22 undefined	-0.17 undefined
2015	0 undefined	-0.15 undefined	-0.13 undefined
2014	0 undefined	-0.12 undefined	-0.22 undefined
2013	0 undefined	-0.13 undefined	-0.24 undefined
2012	0.01 undefined	-0.15 undefined	-0.38 undefined
2011	2 undefined	-0.22 undefined	-2.11 undefined
2010	1.1 undefined	-0.37 undefined	-1.33 undefined
2009	1.11 undefined	0.56 undefined	-0.62 undefined
2008	0.93 undefined	-0.31 undefined	-0.55 undefined
2007	0.67 undefined	0.87 undefined	0.43 undefined
2006	0.62 undefined	1.08 undefined	0.23 undefined
2005	0.62 undefined	0.11 undefined	-0.21 undefined
2004	0.18 undefined	0.04 undefined	-0.06 undefined

	Sales per Share	EBIT per share	Earnings per Share
2004	0.18 GBP	0.04 GBP	-0.06 GBP
2005	0.62 GBP	0.11 GBP	-0.21 GBP
2006	0.62 GBP	1.08 GBP	0.23 GBP
2007	0.67 GBP	0.87 GBP	0.43 GBP
2008	0.93 GBP	-0.31 GBP	-0.55 GBP
2009	1.11 GBP	0.56 GBP	-0.62 GBP
2010	1.1 GBP	-0.37 GBP	-1.33 GBP
2011	2 GBP	-0.22 GBP	-2.11 GBP
2012	0.01 GBP	-0.15 GBP	-0.38 GBP
2013	0 GBP	-0.13 GBP	-0.24 GBP
2014	0 GBP	-0.12 GBP	-0.22 GBP
2015	0 GBP	-0.15 GBP	-0.13 GBP
2016	0 GBP	-0.22 GBP	-0.17 GBP
2017	0 GBP	-0.19 GBP	-0.18 GBP
2018	0 GBP	-0.15 GBP	-0.14 GBP
2019	0 GBP	-0.1 GBP	-0.1 GBP
2020	0 GBP	-0.07 GBP	-0.09 GBP
2021	0 GBP	-0.06 GBP	-0.08 GBP
2022e	0 GBP	0 GBP	-0.07 GBP
2023e	0.06 GBP	0 GBP	-0.05 GBP
2024e	0.19 GBP	0 GBP	-0.02 GBP
2025e	0.28 GBP	0 GBP	0 GBP
2026e	0.33 GBP	0 GBP	0.02 GBP
2027e	0.39 GBP	0 GBP	0.04 GBP

	Number of stocks
2004	3.08 M Aktien
2005	2.83 M Aktien
2006	2.95 M Aktien
2007	3.16 M Aktien
2008	3.08 M Aktien
2009	3.08 M Aktien
2010	3.08 M Aktien
2011	3.08 M Aktien
2012	7.06 M Aktien
2013	16.1 M Aktien
2014	34.02 M Aktien
2015	51.28 M Aktien
2016	60.8 M Aktien
2017	77.83 M Aktien
2018	150.54 M Aktien
2019	211.48 M Aktien
2020	288.98 M Aktien
2021	382.48 M Aktien
2022e	382.48 M Aktien
2023e	382.48 M Aktien
2024e	382.48 M Aktien
2025e	382.48 M Aktien
2026e	382.48 M Aktien
2027e	382.48 M Aktien

%	Name	Stocks	Change	Date
8.43340 %	Yantai CIPU Medical Technology Co Ltd	45,757,097	0	5/2/2023
8.41535 %	Glatz (Philippe)	45,659,162	0	8/17/2022
7.45959 %	Odey Asset Management LLP	40,473,508	-11,099,156	6/28/2023
5.60402 %	Mulligan (Seamus)	30,405,721	0	5/3/2023
5.59068 %	Celeste Management SA	30,333,333	2,000,000	5/2/2023
2.88092 %	eQ Asset Management Oy	15,631,000	125,000	5/10/2023
2.79227 %	DNCA Investments	15,150,000	-7,475,000	3/28/2023
2.31307 %	Baltisches Haus	12,550,000	12,550,000	5/9/2023
2.15341 %	Ahlström Invest B.V.	11,683,761	11,683,761	5/12/2023
2.05213 %	Cosylab D.D.	11,134,257	0	5/23/2023
1.82194 %	Odey Wealth Management (UK) Limited	9,885,325	837,514	4/30/2023
1.74002 %	Sinclair (Michael Jeffrey)	9,440,814	0	5/2/2023
1.53975 %	Bradfield (Michael Stephen)	8,354,240	0	5/2/2023
1.19594 %	Urwitz (Gabriel)	6,488,789	6,366,289	5/16/2023
1.14271 %	Minmetco Ltd	6,200,000	6,200,000	5/12/2023
1.08281 %	Unger (Glen E S de)	5,875,000	5,875,000	5/12/2023
1.06677 %	Atlantic Cedar Ltd	5,788,000	5,788,000	5/10/2023
0.94505 %	M3T Pte. Ltd.	5,127,560	0	1/15/2023
0.86170 %	Plowman (Piers Nicholas)	4,675,304	0	5/2/2023
0.75131 %	Vanni (Enrico Cipro)	4,076,361	0	5/2/2023
0.73723 %	Philipp (Kathleen Glynn)	4,000,000	4,000,000	1/15/2023
0.52528 %	Kambara International KK	2,850,000	0	1/15/2023
0.44105 %	Close Brothers Asset Management	2,393,024	2,243,024	1/15/2023
0.40126 %	Serandour (Nicolas)	2,177,134	0	5/2/2023
0.28476 %	Bradshaw (Mark)	1,545,000	1,545,000	5/9/2023
0.28394 %	Myers (Steve)	1,540,569	-70,000	5/2/2023
0.23039 %	Taylor (Cristina Alicia)	1,250,000	0	1/15/2023
0.21963 %	Courtois (Xavier)	1,191,667	0	1/15/2023
0.18807 %	REYL Intesa Sanpaolo	1,020,408	0	1/15/2023
0.18108 %	Van Celsing (Hans)	982,499	0	5/2/2023
0.15046 %	Purity S.A.	816,326	0	1/15/2023
0.14793 %	Farr (Jonathan)	802,644	0	1/15/2023
0.14745 %	Sofro A/S	800,000	0	1/15/2023
0.11519 %	Lawson (Maurice Day)	625,000	0	1/15/2023
0.10598 %	Bazin (Francois)	575,000	575,000	5/22/2023
0.09403 %	Isbell (Christopher Pascal)	510,190	510,190	5/11/2023
0.09263 %	Horgan (Michael Peter Stephen)	502,563	-79,425	1/15/2023
0.08622 %	Zhang (Ren Hua)	467,781	253,332	1/15/2023
0.07680 %	Karmalawy (Moataz)	416,667	0	1/15/2023
0.07680 %	Pons-Chabord (Berengere)	416,667	0	1/15/2023
0.07372 %	Pike (Jeff)	400,000	400,000	1/15/2023
0.07142 %	Concept Trustees Ltd.	387,500	0	1/15/2023
0.06912 %	Kwist (Jakob Jeroen)	375,000	0	1/15/2023
0.06912 %	Sunny Shores BV	375,000	0	1/15/2023
0.05529 %	Courty (Patrice)	300,000	300,000	1/15/2023
0.05414 %	Cross (Lori J)	293,749	0	5/2/2023
0.05252 %	Chabord (Berengere)	284,933	0	1/15/2023
0.04608 %	Moguda BV	250,000	0	1/15/2023
0.03686 %	Fu (Rong)	200,000	0	1/15/2023
0.03686 %	Rado (Yaron)	200,000	0	1/15/2023
0.03407 %	Investec Wealth & Investment Limited	184,852	-79,000	1/15/2023
0.03318 %	F.Sole s.r.l	180,000	0	1/15/2023
0.03133 %	Badeni (Michael)	170,000	170,000	5/9/2023
0.02944 %	Lancea LLP	159,750	0	1/15/2023
0.02666 %	Han (Chunlin)	144,658	0	1/15/2023
0.02666 %	Huang (Yuelong)	144,658	0	1/15/2023
0.02580 %	Ogunsalu (Samuel Olawole Akinyemi)	140,000	0	1/15/2023
0.02168 %	Lee (Seong Bae)	117,622	0	1/15/2023
0.02101 %	Minshell (Caroline Margaret)	114,000	0	1/15/2023
0.02073 %	Thomson (Euan)	112,500	0	1/15/2023
0.01843 %	Hulsebergen (Wilhelmus)	100,000	100,000	1/15/2023
0.01843 %	Middleditch (Henry)	100,000	100,000	1/15/2023
0 %	Green Ash Partners LLP	0	-4,828,451	7/31/2023
0 %	Milne (Garth Peter Denis)	0	-121,974	7/1/2022
0 %	Brompton Asset Management LLP	0	-611,374	9/30/2023
0 %	Spreadex, Ltd.	0	-206,228	7/31/2022
0 %	Ceresio Investors	0	-559,000	3/31/2023
0 %	Seligson & Co Rahastoyhtiö Oyj	0	-1,900,000	11/30/2023
0 %	Christmas Common Investments Ltd.	0	-2,750,000	7/31/2022
0 %	Greystone Trust Company Ltd.	0	-250,000	7/31/2022
0 %	Angmac, Ltd.	0	-70,000	7/1/2022
0 %	Berkshire Investment Management Ltd	0	-576,667	1/31/2023

Name	Relationship	Two-week correlation	One-month correlation	Three-Month Correlation	Six-Month Correlation	One Year Correlation	Two-Year Correlation
RaySearch Laboratories B	SupplierCustomer	-0,57	-0,07	-0,34	0,58	0,46	0,25

What values and corporate philosophy does Advanced Oncotherapy represent?

Advanced Oncotherapy PLC represents a commitment to innovation, excellence, and patient-centric care in the field of advanced cancer treatment solutions. With a strong focus on delivering cutting-edge proton beam therapy technology, the company aims to revolutionize cancer treatment and enhance patient outcomes. Advanced Oncotherapy PLC is dedicated to providing personalized, precise, and cost-effective therapies to cancer patients worldwide. Its corporate philosophy revolves around advancing the field of oncology through research, collaboration, and continuous improvement. By harnessing state-of-the-art technology and prioritizing patient well-being, Advanced Oncotherapy PLC strives to make a meaningful difference in the fight against cancer.

In which countries and regions is Advanced Oncotherapy primarily present?

Advanced Oncotherapy PLC is primarily present in the United Kingdom.

What significant milestones has the company Advanced Oncotherapy achieved?

Advanced Oncotherapy PLC has achieved several significant milestones. One notable achievement is the successful completion of the first LIGHT system installation at a proton therapy center in Harley Street, London. Additionally, the company has made progress in securing partnerships and collaborations with recognized industry leaders. Advanced Oncotherapy PLC has also demonstrated its commitment to innovation by obtaining regulatory clearances and patents for its cutting-edge technologies. Furthermore, the company continues to advance its research and development efforts, aiming to provide effective and affordable cancer treatment solutions to patients worldwide.

What is the history and background of the company Advanced Oncotherapy?

Advanced Oncotherapy PLC is a leading company in the field of proton therapy technology. Established in 2006, the company is dedicated to advancing cancer treatment by developing and commercializing innovative proton therapy systems. Advanced Oncotherapy PLC aims to make proton therapy more accessible and affordable through its cutting-edge LIGHT system. This system leverages revolutionary technology, optimizing cancer treatment with precise doses of proton beams. The team behind Advanced Oncotherapy PLC consists of experienced professionals, including scientists and engineers, who are committed to making a significant impact on cancer care. With a strong focus on research and development, the company is poised to revolutionize cancer treatment worldwide.

Who are the main competitors of Advanced Oncotherapy in the market?

The main competitors of Advanced Oncotherapy PLC in the market include Varian Medical Systems, Elekta AB, and Accuray Incorporated.

In which industries is Advanced Oncotherapy primarily active?

Advanced Oncotherapy PLC is primarily active in the healthcare industry. With a focus on innovative and advanced technologies, the company offers solutions for the treatment of cancer. Advanced Oncotherapy PLC develops and manufactures state-of-the-art proton therapy systems that aim to provide more precise and effective cancer treatments. By leveraging cutting-edge medical technology, the company strives to contribute to the advancement of cancer care and improve patient outcomes. With its presence in the healthcare sector, Advanced Oncotherapy PLC plays a significant role in addressing the critical needs of cancer patients and medical professionals.

What is the business model of Advanced Oncotherapy?

The business model of Advanced Oncotherapy PLC focuses on developing and providing advanced technologies and innovative solutions for the treatment of cancer. The company specializes in the design, development, and commercialization of proton therapy systems, which enable precise and targeted radiation therapy. Advanced Oncotherapy PLC aims to revolutionize cancer treatment by offering cost-effective and compact proton beam therapy systems that are suitable for both large academic centers and private clinics. By harnessing the power of proton therapy, the company aims to improve patient outcomes while reducing the side effects typically associated with traditional radiation therapy methods.

What is the P/E ratio of Advanced Oncotherapy 2024?

The Advanced Oncotherapy P/E ratio is -0.01.

What is the P/S ratio of Advanced Oncotherapy 2024?

The Advanced Oncotherapy P/S ratio is 0.

What is the Quality Investing of Advanced Oncotherapy?

The Quality Investing for Advanced Oncotherapy is 3/10.

What is the revenue of Advanced Oncotherapy 2024?

The expected Advanced Oncotherapy revenue is 103.31 M GBP.

How high is the profit of Advanced Oncotherapy 2024?

The expected Advanced Oncotherapy profit is -8.94 M GBP.

What is the business model of Advanced Oncotherapy

Advanced Oncotherapy is a medical company specializing in the development and manufacturing of advanced technologies for cancer treatment. Their business model includes technology development as well as providing services and products. The main product is the LIGHT (Linac Image Guided Hadron Technology) radiotherapy platform, which allows for precise targeted treatment of tumors in inaccessible areas of the body or near sensitive tissues using a combination of linear accelerator and hadron technology. They also offer services and products such as biopsy solutions and custom imaging solutions tailored to the specific needs of their customers. Additionally, they invest in research and development and collaborate with research institutions and universities. Their goal is to market and sell their technology globally by collaborating with distributors and governments to integrate their products into healthcare systems worldwide. Advanced Oncotherapy aims to continually innovate and provide better solutions for their customers, positioning them for future growth and success in the cancer treatment market.

What is the Advanced Oncotherapy dividend?

Advanced Oncotherapy pays a dividend of 0 GBP distributed over payouts per year.

How often does Advanced Oncotherapy pay dividends?

The dividend cannot currently be calculated for Advanced Oncotherapy or the company does not pay out a dividend.

What is the Advanced Oncotherapy ISIN?

The ISIN of Advanced Oncotherapy is GB00BD6SX109.

What is the Advanced Oncotherapy WKN?

The WKN of Advanced Oncotherapy is A2AL9X.

What is the Advanced Oncotherapy ticker?

The ticker of Advanced Oncotherapy is AVO.L.

How much dividend does Advanced Oncotherapy pay?

Over the past 12 months, Advanced Oncotherapy paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Advanced Oncotherapy is expected to pay a dividend of 0 GBP.

What is the dividend yield of Advanced Oncotherapy?

The current dividend yield of Advanced Oncotherapy is .

When does Advanced Oncotherapy pay dividends?

Advanced Oncotherapy pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Advanced Oncotherapy?

Advanced Oncotherapy paid dividends every year for the past 0 years.

What is the dividend of Advanced Oncotherapy?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Advanced Oncotherapy located?

Advanced Oncotherapy is assigned to the 'Health' sector.

Wann musste ich die Aktien von Advanced Oncotherapy kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Advanced Oncotherapy from 11/4/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 11/4/2024.

When did Advanced Oncotherapy pay the last dividend?

The last dividend was paid out on 11/4/2024.

What was the dividend of Advanced Oncotherapy in the year 2023?

In the year 2023, Advanced Oncotherapy distributed 0 GBP as dividends.

In which currency does Advanced Oncotherapy pay out the dividend?

The dividends of Advanced Oncotherapy are distributed in GBP.

Stock Exchange	Advanced Oncotherapy Ticker
FRANKFURT	R3I1.F
LONDON	AVO.L
LONDON STOCK EXCHANGE	AVO.L

Advanced Oncotherapy Ticker	Advanced Oncotherapy FIGI
R3I1:GR	BBG000CK4Q81
R3I1:GF	BBG000CK4QL6
R3I1:GS	BBG000CK4SC2
R3I1:GB	BBG000CK4T49
AVO:LN	BBG000PWFPZ1
CARE:EO	BBG000PYJXX8
CARE:XL	BBG000PYK353
CARE:E1	BBG000PYK6R2
CARE:XT	BBG000PYK7W4
CARE:XW	BBG000PYK8F1
CARE:EU	BBG000QCQ1W8
CAREEUR:EO	BBG000QZ22H8
CAREEUR:E1	BBG000QZ28Q5
CAREEUR:XT	BBG000QZ2983
CAREEUR:XW	BBG000QZ29N6
CARE:XV	BBG005918H91
CAREEUR:XV	BBG00591BKB7
AVOL:B3	BBG006T787H7
AVOL:L3	BBG006TB9X44
CAREEUR:EU	BBG008FK0GV1
AVOL:PO	BBG008GZC6V6
CARE:XX	BBG00JN764B0
CAREEUR:XX	BBG00JN78641
CAREEUR:EP	BBG00SXJK329
CAREEUR:EZ	BBG00SXJK347
R3I1:LA	BBG018H87SX0
R3I1:LU	BBG018J1WWJ2

2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022e	2023e	2024e	2025e	2026e	2027e
0	1	1	2	2	3	3	6	0	0	0	0	0	0	0	0	0	0	0	34	103	149	176	211
-	-	-	100.00	-	50.00	-	100.00	-	-	-	-	-	-	-	-	-	-	-	-	202.94	44.66	18.12	19.89
-	100.00	100.00	50.00	100.00	66.67	33.33	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
0	1	1	1	2	2	1	0	0	0	0	0	0	0	-1	0	0	0	0	0	0	0	0	0
0	0	3	2	0	1	-1	0	-1	-2	-4	-7	-13	-14	-21	-20	-20	-23	-27	-26	-9	5	19	39
-	-	300.00	100.00	-	33.33	-33.33	-	-	-	-	-	-	-	-	-	-	-	-	-76.47	-8.74	3.36	10.80	18.48
0	0	0	1	-1	-1	-4	-6	-2	-3	-7	-6	-10	-13	-21	-20	-25	-29	-38	-25	-8	2	10	23
-	-	-	-	-200.00	-	300.00	50.00	-66.67	50.00	133.33	-14.29	66.67	30.00	61.54	-4.76	25.00	16.00	31.03	-34.21	-68.00	-125.00	400.00	130.00
3.08	2.83	2.95	3.16	3.08	3.08	3.08	3.08	7.06	16.1	34.02	51.28	60.8	77.83	150.54	211.48	288.98	382.48	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Access the world's leading financial data and tools

Price

Price

TickerAVO.L

ISINGB00BD6SX109

WKNA2AL9X

Advanced Oncotherapy stock price

Price

Overview

Intraday Feature

Total Return and Relative Price Change

Interpretation and Investment

Advanced Oncotherapy Stock Price History

Advanced Oncotherapy Revenue, EBIT, Net Income GB00BD6SX109 · A2AL9X

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Yearly Analysis and Comparisons

Utilizing Expectations for Investment

Investment Insights

Advanced Oncotherapy Revenue, EBIT and net profit per share

Advanced Oncotherapy Income Statement, Balance Sheet, Cash Flow Statement

Keystats

Revenue and Growth

Gross Margin

EBIT and EBIT Margin

Income and Growth

Shares Outstanding

Interpreting Year to Year Comparison

Expectations and Predictions

Balance Sheet

Understanding the Balance Sheet

Assets

Liabilities

Equity

Year-to-Year Analysis

Interpreting the Data

Advanced Oncotherapy stock margins GB00BD6SX109 · A2AL9X

Margin

Understanding Gross Margin

EBIT Margin Analysis

Revenue Margin Insights

Interpreting Expectations

Comparative Analysis

Advanced Oncotherapy Margin History

Advanced Oncotherapy Stock Sales Revenue, EBIT, Earnings per Share GB00BD6SX109 · A2AL9X

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

Advanced Oncotherapy Revenue, EBIT and net profit per share

Advanced Oncotherapy business model

Advanced Oncotherapy SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

Advanced Oncotherapy Eulerpool Fair Value

Fair Value

Understanding Fair Value

Income-Based Fair Value

Revenue-Based Fair Value

Dividend-Based Fair Value

Expectations and Forecasts

Comparative Analysis

Advanced Oncotherapy historical P/E ratio, EBIT multiple, and P/S ratio

Advanced Oncotherapy shares outstanding GB00BD6SX109 · A2AL9X

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

Advanced Oncotherapy stock splits

The World’s Best Investors Are On Eulerpool

Advanced Oncotherapy Earnings Estimates

Advanced Oncotherapy latest earnings and earnings surprises

Advanced Oncotherapy shareholders

Advanced Oncotherapy Executives and Management Board

Advanced Oncotherapy Supply Chain

Most common questions regarding Advanced Oncotherapy

Ticker
AVO.L

ISIN
GB00BD6SX109

WKN
A2AL9X